



Tumor Microenvironment and Immunotherapy in Head and Neck Cancer

Guest Editor:

Dr. Marco Carlo Merlano

Chair, Head and Neck Cancer
Multidisciplinary Team,
Department of Medical Oncology,
Candiolo Cancer Institute, FPO-
IRCCS, 10060 Turin, Italy

Deadline for manuscript
submissions:

closed (31 October 2022)

Message from the Guest Editor

Dear Colleagues,

The tumor microenvironment drives cancer immune phenotype and allows for the identification of inflamed tumors, excluded tumors and deserted tumors. In head and neck cancer (HNC), all the three phenotypes may be represented regardless of etiology. This implies that the first step to approach HNC is to identify which immunophenotype we are facing. Indeed, each phenotype shows distinctive escape mechanisms. Consequently, each immunophenotype requires the reactivation or the inhibition of distinct immune pathways. Therefore, the best immunotherapy approach to head and neck cancer depends on the dominant escape mechanism which, in turn, links to the immune phenotype.

In conclusion, the challenge of immunotherapy in HNC is first of all to identify the immunophenotype of the single tumor we are facing; second, to identify potential specific targets of the phenotype; third, to develop drugs directed against the targets; and finally, to test the drug(s) in clinical practice. The goal is to lead to a more informed use of immunotherapy, better selecting the patients to be treated and with which drug.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI